News and Events

Careful counsel required when discussing the possibility of receiving treatment with immunotherapy

3 May 2019

This recent Australian study explores the perspectives of patients undergoing immunotherapy for melanoma and focus on factors that influenced their treatment decision‐making. Results showed that the hope immunotherapy provided to patients meant careful counsel was required when discussing the possibility of receiving immunotherapy treatments to ensure patients adequately understand the trade‐off between efficacy and toxicity. 

Development and initial validation of a self-efficacy for skin self-examination scale

18 April 2019

This Canadian study reports on the development and initial validation of a measure assessing self-efficacy for skin self-examination. According to the study, the scale has potential for use by nurses and other health professionals in follow-up care to identify individuals who require more targeted educational skin self-examination interventions.

Rural GPs require structured follow-up practice for melanoma

18 April 2019

This recent study evaluated post-treatment surveillance practices for both melanotic and non-melanotic skin cancers (NMSC) by general practitioners (GPs) in regional Victoria, Australia. With 66% (43/65) of survey respondents reported using a structured follow-up practice for melanoma, it suggests rural GPs require a structured follow up practice for melanoma patients. Patient's level of education, time constraints, practitioner accessibility and specialists' availability were identified as common challenges in follow-up. 

Concerns about Vitamin D should not negate skin cancer prevention advice

18 April 2019

This recent systematic review summarises latest evidence of the relationship between sunscreen use and vitamin D. According to the review there is little evidence that sunscreen decreases 25(OH)D concentration when used in real life settings, suggesting concerns about vitamin D should not negate skin cancer prevention advice. However, there have been no trials of the high sun protection factor sunscreens that are now widely recommended.